Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TsumuraTSMRF 79 EV-to-EBIT is 8.76 as of Aug. 04, 2026, which is 22% below its 10-year median of 11.22. GuruFocus rates TSMRF with a GF Score™ of 79/100 and a GF Value™ of $25.74. The stock has 4 warning signs investors should review. Among 691 Drug Manufacturers companies, Tsumura ranks better than 74.38% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tsumura's Enterprise Value is $2,421 Mil.
Tsumura's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $276 Mil. Therefore, Tsumura's EV-to-EBIT for today is 8.76.
The historical rank and industry rank for Tsumura's EV-to-EBIT or its related term are showing as below:
TSMRF'
s EV-to-EBIT Range Over the Past 10 Years
Min: 6.07 Med: 11.22 Max: 18.9
Current: 9.13
During the past 13 years, the highest EV-to-EBIT of Tsumura was 18.90. The lowest was 6.07. And the median was 11.22.
TSMRF's EV-to-EBIT is ranked better than 74.38% of 691
companies
in the Drug Manufacturers industry
Industry Median: 15.68
vs TSMRF: 9.13
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Tsumura's Enterprise Value for the quarter that ended in Mar. 2026 was $2,366 Mil.
Tsumura's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $276 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsumura EV-to-EBIT Related Terms
Tsumura EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Tsumura's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tsumura's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsumura EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tsumura's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Tsumura's EV-to-EBIT falls into.
Tsumura's current Enterprise Value is $2,421 Mil.
Tsumura's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $276 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsumura (TSMRF) has a EV-to-EBIT of 8.76 as of Aug. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tsumura and its competitors. This is 22% below median its historical median of 11.22. Over the past decade, Tsumura's EV-to-EBIT has ranged from 6.07 to 18.90. According to the industry distribution chart, Tsumura ranks #177 out of 691 companies in the Drug Manufacturers industry, placing it in the top 25.6%.
Is Tsumura's EV-to-EBIT too high?
Tsumura's current EV-to-EBIT of 8.76 is 22% below median its 10-year median of 11.22. Over the past 10 years, this metric has ranged from a low of 6.07 to a high of 18.90. The Drug Manufacturers industry median EV-to-EBIT is 15.68. Tsumura's value of 8.76 is 44.1% below this industry median. Based on the distribution chart, Tsumura ranks #177 out of 691 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tsumura has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Tsumura's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tsumura ranks #177 out of 691 companies for EV-to-EBIT. This puts Tsumura in the upper half of its industry. The industry median EV-to-EBIT is 15.68. Tsumura's value of 8.76 is 44.1% below this benchmark. Historically, Tsumura's own EV-to-EBIT has ranged from 6.07 to 18.90 over the past decade. While the company's 10-year median is 11.22 vs. the industry median of 15.68, Tsumura has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tsumura's current EV-to-EBIT of 8.76 is 44.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tsumura and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsumura's current EV-to-EBIT is 8.76, which is 22% below median its own 10-year median of 11.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsumura stock overvalued right now?
Tsumura (TSMRF) has a current EV-to-EBIT of 8.76. The stock's GF Value™ is $25.74, compared to a current price of $23.20 — trading 9.9% below its estimated fair value. The current EV-to-EBIT is 8.76, which is 22% below median its 10-year median of 11.22 and 44.1% below the Drug Manufacturers industry median of 15.68. Tsumura's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Tsumura (TSMRF), the current EV-to-EBIT is 8.76 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsumura (TSMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Tsumura stock appears to be undervalued.
The current stock price of $23.20 is trading 9.9% below its estimated GF Value™ of $25.74.
Key valuation signals for TSMRF:
EV-to-EBIT: 8.76 (22% below median its 10-year median of 11.22)
GF Value™: $25.74 vs. price of $23.20 (9.9% below fair value)
Industry Position: 44.1% below the Drug Manufacturers median (#177 of 691)
No single metric tells the full story. See the TSMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates the majority of its revenue through prescription Kampo products, followed by over-the-counter medicines. It promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company specializes in developing, producing, and marketing Kampo formulations that integrate traditional herbal knowledge with modern pharmaceutical science to address various health conditions.
79GF Score
Get the complete analysis for TSMRF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSMRF has been successfully added to your 
